Blueprint Medicines Corporation (NASDAQ:BPMC) Q2 2022 Earnings Conference Call August 2, 2022 8:00 AM ET
Company Participants
Jenna Cohen - Senior Director and Head of Investor Relations
Kate Haviland - Chief Executive Officer
Philina Lee - Chief Commercial Officer
Becker Hewes - MD, Chief Medical Officer
Christy Rossi - Chief Operating Officer
Mike Landsittel - Chief Financial Officer
Conference Call Participants
Ernie Rodriguez - Cowen and Company
Dane Leone - Raymond James
Andrea Tan - Goldman Sachs
Peter Lawson - Barclays
Reni Benjamin - JMP Securities
Eun Yang - Jefferies
Brad Canino - Stifel
David Nierengarten - Wedbush Securities
Paul Jeng - Guggenheim Securities
David Lebowitz - Citi
Joel Beatty - Baird
Matthew Biegler - Oppenheimer
Operator
Good morning. My name is Charlie, and I’ll be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicine's Second Quarter 2022 Financial Results Conference Call. [Operator Instructions] After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions] Thank you.
Jenna Cohen, you may begin your conference.
Jenna Cohen
Thank you, Charlie. Good morning, everyone, and welcome to Blueprint Medicines second quarter 2022 financial and operating results conference call. This morning we issued a press release, which outlines the topics we plan to discuss today. You can access the press release, as well as the slides that we'll be reviewing today by going to the Investors Section of our website at www.blueprintmedicines.com.
Joining me on today’s call are Kate Haviland, our Chief Executive Officer, who will discuss our successes in the second quarter and a look ahead to the second half of the year; Philina Lee, our Chief Commercial Officer who will provide a commercial update; Becker Hewes, Chief Medical Officer who will provide a clinical update; Christy Rossi, Chief Operating Officer, who will review our 2022 milestone progress and upcoming catalysts; and Mike Landsittel, our Chief Financial Officer who will review our second quarter 2022 financial results.
Before we get started, I would like to remind everyone that statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in the Risk Factors section of SEC filings.
In addition, any forward-looking statement made on this call represents our views only as of today and should not be relied upon as representing our views as of any subsequent date. Except as required by law, we specifically disclaim any obligation to update or revise any forward-looking statements.